Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma-Reference-Cited by-同舟云学术

Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma

Published:2023-07-04 Issue:5 Volume:18 Page:190-200
ISSN:1558-8211
Container-title:Current Hematologic Malignancy Reports
language:en
Short-container-title:Curr Hematol Malig Rep

Author:

Teo Winnie Z. Y.,Ong Ian Y. E.,Tong Jason W. Y.,Ong Wan Li,Lin Adeline,Song Fangfang,Tai Bee Choo,Ooi Melissa,Seokojo Cinnie Yentia,Chen Yunxin,Nagarajan Chandramouli,Chng Wee Joo,de Mel Sanjay^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

https://link.springer.com/content/pdf/10.1007/s11899-023-00704-9.pdf

Reference52 articles.

1. van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. The Lancet. 2021;397(10272):410–27.

2. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94.

3. Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31(26):3279–87.

4. Jackson GH, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, et al. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, phase III trial. Br J Haematol. 2021;192(5):853–68.

5. Chong LL, Soon YY, Soekojo CY, Ooi M, Chng WJ, de Mel S. Daratumumab-based induction therapy for multiple myeloma: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159.